AAAAAA

   
Results: 1-12 |
Results: 12
Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing
Authors: Sarriera, JE Albitar, M Estrov, Z Gidel, C Aboul-Nasr, R Manshouri, T Kornblau, S Chang, KS Kantarjian, H Estey, E
Citation: Je. Sarriera et al., Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing, LEUKEMIA, 15(1), 2001, pp. 57-61
Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation
Authors: Champlin, R Khouri, I Anderlini, P Gajewski, J Kornblau, S Molldrem, J Shimoni, A Ueno, N Giralt, S
Citation: R. Champlin et al., Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation, BONE MAR TR, 27, 2001, pp. S13-S22
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia
Authors: Giles, F Cortes, J Garcia-Manero, G Kornblau, S Estey, E Kwari, M Murgo, A Kantarjian, H
Citation: F. Giles et al., Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia, INV NEW DR, 19(1), 2001, pp. 13-20
Clinical significance of fragile histidine triad gene expression in adult acute lymphoblastic leukemia
Authors: Albitar, M Manshouri, T Gidel, C Croce, C Kornblau, S Pierce, S Kantarjian, HM
Citation: M. Albitar et al., Clinical significance of fragile histidine triad gene expression in adult acute lymphoblastic leukemia, LEUK RES, 25(10), 2001, pp. 859-864
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Authors: Giralt, S Thall, PF Khouri, I Wang, XM Braunschweig, I Ippolitti, C Claxton, D Donato, M Bruton, J Cohen, A Davis, M Andersson, BS Anderlini, P Gajewski, J Kornblau, S Andreeff, M Przepiorka, D Ueno, NT Molldrem, J Champlin, R
Citation: S. Giralt et al., Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation, BLOOD, 97(3), 2001, pp. 631-637
Management of cancer treatment-related diarrhea: Issues and therapeutic strategies
Authors: Kornblau, S Benson, AB Catalano, R Champlin, RE Engelking, C Field, M Ippoliti, C Lazarus, HM Mitchell, E Rubin, J Stiff, PJ Vokes, E Wadler, S
Citation: S. Kornblau et al., Management of cancer treatment-related diarrhea: Issues and therapeutic strategies, J PAIN SYMP, 19(2), 2000, pp. 118-129
Harnessing graft-versus-malignancy: Non-myeloablative preparative regimensfor allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy
Authors: Champlin, R Khouri, I Shimoni, A Gajewski, J Kornblau, S Molldrem, J Ueno, N Giralt, S Anderlini, P
Citation: R. Champlin et al., Harnessing graft-versus-malignancy: Non-myeloablative preparative regimensfor allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy, BR J HAEM, 111(1), 2000, pp. 18-29
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia
Authors: Sacchi, S Kantarjian, HM Freireich, EJ O'Brien, SO Cortes, J Rios, MB Kornblau, S Giles, FJ Koller, C Gajewski, J Talpaz, M
Citation: S. Sacchi et al., Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia, LEUK LYMPH, 35(5-6), 1999, pp. 483-489
Allogeneic hematopoietic transplantation as adoptive immunotherapy - Induction of graft-versus-malignancy as primary therapy
Authors: Champlin, R Khouri, I Kornblau, S Marini, F Anderlini, P Ueno, NT Molldrem, J Giralt, S
Citation: R. Champlin et al., Allogeneic hematopoietic transplantation as adoptive immunotherapy - Induction of graft-versus-malignancy as primary therapy, HEMAT ONCOL, 13(5), 1999, pp. 1041
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia
Authors: Beran, M Estey, E O'Brien, S Cortes, J Koller, CA Giles, FJ Kornblau, S Andreeff, M Vey, N Pierce, SR Hayes, K Wong, GC Keating, M Kantarjian, H
Citation: M. Beran et al., Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia, J CL ONCOL, 17(9), 1999, pp. 2819-2830
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine
Authors: Kantarjian, HM O'Brien, S Smith, TL Rios, MB Cortes, J Beran, M Koller, C Giles, FJ Andreeff, M Kornblau, S Giralt, S Keating, MJ Talpaz, M
Citation: Hm. Kantarjian et al., Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine, J CL ONCOL, 17(1), 1999, pp. 284-292
Results of topotecan single-agent therapy in patients with myelodysplasticsyndromes and chronic myelomonocytic leukemia
Authors: Beran, M Estey, E O'Brien, SM Giles, FJ Koller, CA Kornblau, S Keating, M Kantarjian, HM
Citation: M. Beran et al., Results of topotecan single-agent therapy in patients with myelodysplasticsyndromes and chronic myelomonocytic leukemia, LEUK LYMPH, 31(5-6), 1998, pp. 521-531
Risultati: 1-12 |